ImmunityBio完成关键随机试验患者招募:评估Anktiva®联合BCG对比单用BCG治疗BCG初治非肌层浸润性膀胱癌原位癌

美股速递
Feb 26

ImmunityBio, Inc. (简称ImmunityBio) 已顺利完成一项关键性随机试验的患者招募工作。该试验旨在评估其核心产品Anktiva®联合卡介苗(BCG)的治疗方案,对比单用BCG,在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。

这项研究的完成标志着公司在膀胱癌创新疗法开发领域迈出了重要一步,为后续的数据分析和结果公布奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10